Acquisitions and Joint Ventures
Acquired a comprehensive list of ANDAs and generic products from Takeda Pharmaceuticals
Acquired a developer of a dermatological device used to treat actinic keratoses
Joint Venture with a focus on emerging markets
Acquired majority stake in a multinational generic manufacturer with established North America presence and a strong dermatology franchise
Acquired a manufacturer of controlled substances with an API facility
Acquired controlled substance manufacturing assets.
Acquired Alkaloida’s controlled substance APIs and dosage form manufacturing plant.
Acquired manufacturer of cephalosporin API holding USA and European approvals
Helped initiate entry in ophthalmology
Initial stake investment in 1996, 100% takeover in 1999. Acquired Cephalexin and 7ADCA actives manufacturing site
Initial stake investment in 1996, 100% takeover in 2002. Acquired plant with USFDA and UKMHRA approvals for oral dosage forms
Helped initiate entry in chest and respiratory therapy areas
Helped initiate entry in oncology and gynecology
Acquired an API plant in Ahmednagar, Maharashtra
* All logos and trademarks are the property of the relevant trademark owners